Skip to main content
    • Aa
    • Aa

The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review*

  • E Ernst (a1) and MH Pittler (a1)

Feverfew (Tanacetum parthenium L.) is a popular herbal remedy often advocated for the prevention of migraine. The aims of this systematic review are to update the evidence from rigorous clinical trials for or against the efficacy of feverfew for migraine prevention and to provide a safety profile of this herbal remedy.


Literature searches were performed using the following databases: Medline, Embase, Biosis, CISCOM and the Cochrane Library (all from their inception to December 1999). Only randomized, placebo-controlled, double-blind trials of feverfew mono-preparations for the prevention of migraine in human subjects were included. All articles were read by two independent reviewers. Data were extracted in a pre-defined, standardized fashion. The methodological quality of the trials was evaluated by the Jadad score. For the assessment of safety issues, major reference texts were also consulted.


Six trials met the inclusion/exclusion criteria. The majority favour feverfew over placebo. Yet important caveats exist. The data also suggest that feverfew is associated with only mild and transient adverse effects and few other safety concerns.


Feverfew is likely to be effective in the prevention of migraine. There are no major safety problems.

    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review*
      Available formats
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review*
      Available formats
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review*
      Available formats
Corresponding author
Corresponding author: Email
Hide All

A previous version of a similar paper was first published in 1998 (Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998; 18: 704–8).

Hide All
1: Eisenberg DM, David RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997. JAMA 1998; 280: 1569–75.
2: Heptinstall S, White A, Williamson L, Mitchel. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1998; i: 1071–4.
3: De Weerdt CJ, Bootsma HPR, Hendriks. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1998; 3: 225–30.
4: Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin. Trials 1996; 17: 112.
5: Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1998; 291: 569–73.
6: Murphy JJ, Heptinstall S, Mitchell JRA. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1998; i: 189–92.
7: Palevitch D, Earon G, Carasso. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother. Res. 1998; 11: 508–11.
8: Kuritzky A, Elhacham Y, Yerushalmi Z, Hering. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1998; 44(Suppl. 2): 293P.
9: Pfaffenrath V, Fischer M, Friede M, Heinneicke V, Zepelin HH. Clinical dose–response study for the investigation of efficacy and tolerability of. Tanacetum parthenium in migraine prophylaxis. Proceedings of Deutscher Schmerzkongress 1998.
10: Fetow CW, Avila JR. Complementary and Alternative Medicines. Springhouse: Philadelphia, 1999.
11: Boon H, Smith M. The Botanical Pharmacy. Kingston, Canada: Quarry Press, 1999.
12: Ernst E. Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. Perfusion 2000; 13: 415.
13: Lininger SW. A–Z Guide to Drug–Herb–Vitamin Interactions. Rocklin, CA: Prima Publishing, 1999.
14: Newall CA, Anderson LA, Phillipson JD. Herbal Medicines. London: The Pharmaceutical Press, 1996.
15: Brinker R. Herb Contraindications and Drug Interactions. Sandy, OR: Eclectic Medical Publications, 1998.
16: Tfelt-Hansen P, Nielsen SL. Patient numbers needed in prophylactic migraine trials. Neuroepidemiology 1997; 6: 214–19.
17: Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J. Pharm. Pharmacol. 1987; 39: 459–65.
18: Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J. Pharm. Pharmacol. 1988; 40: 743–5.
19: Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukotrienes Med. 1982; 8: 653–60.
20: Awang DVC. Prescribing therapeutic feverfew (Tanacetum parthenium (L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integrative Med. 1998; 1: 1113.
21: Goadsby PJ. How do the currently used prophylactic agents work in migraine?. Cephalalgia 1997; 17: 8592.
22: Brown AMG, Edwards CM, Davey MR, Power B, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): Assessment by inhibition of human polymorphonuclear leucocyte chemiluminescence in-vitro. J. Pharm. Pharmacol. 1998; 49: 558–61.
23: Hendriks H, Bos R, Woerdenbag HJ. The essential oil of Tanacetum parthenium (L.) Schultz-Bip. Flavour Fragrance J. 1996; 11: 367–71.
24: Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997; 350: 1598–9.
25: Brun J, Claustrat B, Saddier P, Chazor G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995; 15: 136–9.
26: Willigmann J, Freudenstein J. Production of a stable feverfew (Tanacetum parthenium) extract as an active substance for a pharmaceutical product. Scharper Brümmer 1999 (internal document).
27: Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Hum. Toxicol. 1988; 7: 145–52.
28: Burry JN. Compositae dermatitis in South Australia: Contact dermatitis from Chrysanthemum parthenium. Contact Dermatitis 1980; 6: 445.
29: Hausen BM, Osmundsen PE. Contact allergy to parthenolide in Tanacetum parthenium (L.) Schulz-Bip. (Feverfew, Asteraceae) and cross-reactions to related sesquiterpene lactone containing compositae species. Acta Derm. Venereol. 1983; 63: 308–14.
30: Johnson ES. Patients who chew chrysanthemum leaves. MIMS Mag. 1983; 15 05: 32–5.
31: Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867–72.
32: Ernst E, Pittler MH. Alternative therapy bias [letter]. Nature 1997; 385: 480.
33: Pittler MH, Abbot NC, Harkness EF, Ernst E. Location bias in controlled clinical trials of complementary medicine. J. Clin. Epidemiol. 2000; 53: 485–9.
34: Ernst E, ed. Herbal Medicine. A Concise Overview for Professionals. Oxford: Butterworth-Heinemann, 2000.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Public Health Nutrition
  • ISSN: 1368-9800
  • EISSN: 1475-2727
  • URL: /core/journals/public-health-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 4
Total number of PDF views: 332 *
Loading metrics...

Abstract views

Total abstract views: 436 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd October 2017. This data will be updated every 24 hours.